TY  - JOUR
A1  - Schmitt, Jana
A1  - Backes, Christina
A1  - Nourkami-Tutdibi, Nasenien
A1  - Leidinger, Petra
A1  - Deutscher, Stephanie
A1  - Beier, Markus
A1  - Gessler, Manfred
A1  - Graf, Norbert
A1  - Lenhof, Hans-Peter
A1  - Keller, Andreas
A1  - Meese, Eckart
T1  - Treatment-independent miRNA signature in blood of wilms tumor patients
JF  - BMC Genomics
N2  - Background
Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to SIOP protocol 2001.
Results
We did not find a significant difference between miRNA signature of both groups. However both, Wilms tumor patients prior and after chemotherapy showed a miRNA signature different from healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls.
Conclusion
Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment.
KW  - miRNA
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124034
VL  - 13
IS  - 379
ER  - 
TY  - JOUR
A1  - Keller, Andreas
A1  - Leidinger, Petra
A1  - Vogel, Britta
A1  - Backes, Christina
A1  - ElSharawy, Abdou
A1  - Galata, Valentina
A1  - Mueller, Sabine C.
A1  - Marquart, Sabine
A1  - Schrauder, Michael G.
A1  - Strick, Reiner
A1  - Bauer, Andrea
A1  - Wischhusen, Jörg
A1  - Beier, Markus
A1  - Kohlhaas, Jochen
A1  - Katus, Hugo A.
A1  - Hoheisel, Jörg
A1  - Franke, Andre
A1  - Meder, Benjamin
A1  - Meese, Eckart
T1  - miRNAs can be generally associated with human pathologies as exemplified for miR-144*
JF  - BMC MEDICINE
N2  - Background: miRNA profiles are promising biomarker candidates for a manifold of human pathologies, opening new avenues for diagnosis and prognosis. Beyond studies that describe miRNAs frequently as markers for specific traits, we asked whether a general pattern for miRNAs across many diseases exists. 
Methods: We evaluated genome-wide circulating profiles of 1,049 patients suffering from 19 different cancer and non-cancer diseases as well as unaffected controls. The results were validated on 319 individuals using qRT-PCR. 
Results: We discovered 34 miRNAs with strong disease association. Among those, we found substantially decreased levels of hsa-miR-144* and hsa-miR-20b with AUC of 0.751 ( 95% CI: 0.703-0.799), respectively. We also discovered a set of miRNAs, including hsa-miR-155*, as rather stable markers, offering reasonable control miRNAs for future studies. The strong downregulation of hsa-miR-144* and the less variable pattern of hsa-miR-155* has been validated in a cohort of 319 samples in three different centers. Here, breast cancer as an additional disease phenotype not included in the screening phase has been included as the 20th trait. 
Conclusions: Our study on 1,368 patients including 1,049 genome-wide miRNA profiles and 319 qRT-PCR validations further underscores the high potential of specific blood-borne miRNA patterns as molecular biomarkers. Importantly, we highlight 34 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers.
KW  - peripheral blood
KW  - microna profiles
KW  - disease
KW  - signature
KW  - expression
KW  - miRNA
KW  - microarray
KW  - biomarker
KW  - bioinformatics
KW  - lung-cancer
KW  - multiple sclerosis
KW  - gene
KW  - serum
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-114349
SN  - 1741-7015
VL  - 12
ER  -